Revlimid vs Xtandi
Side-by-side cost comparison based on Medicare Part D data
Revlimid
Lenalidomide
Manufactured by Bristol-Myers Squibb
Xtandi
Enzalutamide
Manufactured by Astellas/Pfizer
Xtandi costs 27% less per claim than Revlimid ($9,331.00 vs $12,786.00). A generic version of Xtandi is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Revlimid | Xtandi |
|---|---|---|
| Avg Cost Per Claim | $12,786.00 | $9,331.00 |
| Total Medicare Spending | $7.8B | $4.1B |
| Total Beneficiaries | 58,000 | 46,000 |
| Total Claims | 612,000 | 438,000 |
| Annual Cost/Patient | $134,914.00 | $88,848.00 |
| Year-over-Year Change | -3.4% | +9.4% |
| Generic Available | No | Yes |
| Patent Expiration | Mar 15, 2027 | Jan 31, 2023 |
| Manufacturer | Bristol-Myers Squibb | Astellas/Pfizer |
| Condition | Cancer | Cancer |
| Generic Name | Lenalidomide | Enzalutamide |
Revlimid vs Xtandi: What the Data Shows
Revlimid (Lenalidomide) and Xtandi (Enzalutamide) are both used to treat cancer. Based on Medicare Part D data, Xtandi costs $9,331.00 per claim, which is 27% less than Revlimid at $12,786.00 per claim.
Medicare spent $7.8B on Revlimid and $4.1B on Xtandi. In terms of patient reach, Revlimid serves more beneficiaries (58,000 vs 46,000).
Year-over-year spending changed -3.4% for Revlimid and +9.4% for Xtandi.
Xtandi has a generic available, while Revlimid remains brand-only until its patent expires Mar 15, 2027.
Frequently Asked Questions
Xtandi is cheaper at $9,331.00 per claim, compared to $12,786.00 for Revlimid. That makes Xtandi about 27% less expensive per claim based on Medicare Part D data.
Yes, both Revlimid and Xtandi are used to treat cancer. Your doctor can help determine which medication is more appropriate for your specific situation.
Xtandi has a generic version (Enzalutamide) available, which is typically much cheaper. Revlimid is currently brand-only, with patent expiring Mar 15, 2027.
Medicare Part D spent $7.8B on Revlimid covering 58,000 beneficiaries, and $4.1B on Xtandi covering 46,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Revlimid and Xtandi on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.